Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Basal Cell 6 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Pancreatic Neoplasms 3 Cholangiocarcinoma 3 Tongue Neoplasms 2 Pleural Diseases 2 Mycosis Fungoides 2 Mesothelioma, Malignant 2 Keratosis, Actinic 2 Bile Duct Neoplasms 2 Basal Cell Nevus Syndrome 2 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Stomatitis 1 Skin Neoplasms 1 Sezary Syndrome 1 Salivary Gland Neoplasms 1 Photosensitivity Disorders 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pain 1 Neoplasms 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoid Interstitial Pneumonia 1 Lung Neoplasms 1 Esthesioneuroblastoma, Olfactory 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Epitheliod Malignant Pleural Mesothelioma 1 Colorectal Neoplasms 1

Interventions

toripalimab 1 durvalumab 1 advexin 1 Surveys and Questionnaires 1 Sampling Studies 1 Nivolumab 1 Mitomycin 1 Mastectomy, Subcutaneous 1 Magnetic Resonance Imaging 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Docetaxel 1 Cystoscopy 1 Cholecalciferol 1 Blood Specimen Collection 1 Biopsy 1 Aminolevulinic Acid 1 1-phenyl-3,3-dimethyltriazene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma in Situ × 1-phenyl-3,3-dimethyltriazene × Clear all

NCT02698293 2022-11-22

PDT Plus Vitamin D3 for Anal Dysplasia

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn

Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon ⚡